Forge to Present at ASGCT's 27th Annual Meeting

April 30, 2024 Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting COLUMBUS, OHIO April 30, 2024 – Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced that it will deliver nine presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27 th Annual Meeting, taking place May 7-11, 2024, in Baltimore, Maryland. The presentations include a late-breaking oral presentation, three technical session presentations, and five scientific posters spanning Forge’s process development, molecular development, integrated regulatory services, and clinical program advancements. “As we continue to advance how genetic medicines are manufactured, we are thrilled to present data showcasing our novel molecular findings, platform process improvements, and regulatory knowledge all centered around efficient, safe, and scalable manufacturing of AAV gene therapies,” said Timothy J. Miller, Ph.D., President and CEO of Forge. “We are also especially encouraged by a late-breaking oral presentation that our Chief Medical Officer, Dr. Maria Escolar, will be delivering that provides a clinical update on FBX-101 where all five patients with Krabbe disease receiving Forge’s gene therapy are walking—a remarkable result. Retention of gross-motor function is one of the most visible and debilitating symptoms seen in patients with Krabbe disease, so this finding is a meaningful clinical outcome.” ORAL PRESENTATION Title: REKLAIM, A Phase 1b Clinical Trial Using a Novel Immune Modulation Strategy for Systemic Administration of FBX-101 (AAVrh10.GALC) After Umbilical Cord Blood Transplantation for the Treatment of Infantile Krabbe Disease Presenter: Maria Escolar, M.D., Chief Medical Officer Date and Time: Friday, May 10, 2024, 8:00-8:15 a.m. ET Room: Ballroom 4 SESSION PRESENTATIONS ASGCT Workshop Title: Preparing for CMC Success: How Early CMC Decision Drives Your Pace and Success to the Clinic Presenter: David Dismuke, Ph.D., Chief Technical Officer Date and Time: Tuesday, May 7, 8:25 a.m. ET Location: Ballroom 3 Tools & Technology Forum Title: Improving Analytical Tools for AAV Characterization Presenter: David Dismuke, Ph.D., Chief Technical Officer Date and Time: Wednesday, May 8, 2:15-2:30 p.m. ET Location: Exhibit Hall Theater Sponsored Symposium Title: Forge’s Discovery and Modification of Genetic Elements for Enhanced Productivity and Efficacy of AAV-based Gene Therapies Presenters: Angela Adsero, Ph.D., Molecular Development Scientist II Frank Agbogbo, Ph.D., VP of Process Development David Dismuke, Ph.D., Chief Technical Officer Date and Time: Thursday, May 9, 1:30-2:00 p.m. ET Location: Room 337-338 POSTER PRESENTATIONS Title: Development of a Scalable Upstream Process for Suspension HEK 293 rAAV Production in Single-Use Bioreactors for Efficient Manufacturing of Gene Therapy Products Presenter: Danielle Sexton, Senior Scientist II, Process Development Date and Time: May 8, 12:00 p.m. ET Poster number: 528 Title: From Benchtop to Cleanroom; Designing an Optimized Platform Purification Process for rAAV Production to Meet the Growing Demand Presenter: Blake Gursky, Scientist II, Process Development Date and Time: May 8, 12:00 p.m. ET Poster number: 527 Title: The Potential of Global Regulatory Harmonization in Gene and Cell Therapy Presenter: Claire Marasco, Associate Director, Regulatory Affairs Date and Time: May 8, 12:00 p.m. ET Poster number: 526 Title: Regulatory Agility: Value of CDMOs Utilizing Platform Technology Presenter: Angela Coy, Ph.D., Senior Manager, Regulatory Affairs Date and Time: May 8, 12:00 p.m. ET Poster number: 905 Title: The Sixth Element: Identification and Evaluation of the Adenovirus L4 22/33K Region as a Requirement for Adeno-Associated Virus Production Presenter: Angela Adsero, Ph.D., Molecular Development Scientist II, Forge Biologics Date and Time: May 9, 12:00 p.m. ET Poster number: 954 Full abstracts are available on the ASGCT Annual Meeting website , and conference participants can also access posters through the ASGCT website. Forge Biologics will be at booth #827 in the Exhibitor Hall. About Forge Biologics Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company, enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 200,000L of manufacturing capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com . Media Inquiries Marina Corleto Associate Director, Marketing and Communications [email protected] Families and Clinician Inquiries Maria Escolar, M.D. Chief Medical Officer [email protected] Business Development Magdalena Tyrpien Chief Business Officer [email protected] by Forge Biologics April 30, 2024 Related Articles July 21, 2026 Restore Vision and Forge Announce AAV Manufacturing Partnership “Providing a new visual restoration treatment option for patients living with retinitis pigmentosa is central to our mission,” said Yusaku Katada, M.D.,... June 16, 2026 Skylark Bio and Forge Announce Strategic AAV Development and cGMP Manufacturing Partnership Under the partnership, Forge is providing Skylark with process development, current good manufacturing practice (cGMP) manufacturing, and analytical... May 11, 2026 Forge Announces Seven Presentations at the ASGCT 29th Annual Meeting “At ASGCT, we’re proud to showcase how our FUEL™ platform is enabling more doses per batch, improving scalability for broader... May 5, 2026 Epicrispr Biotechnologies and Forge Announce AAV Development and cGMP Manufacturing Partnership Epicrispr Biotechnologies and Forge announce a strategic partnership to support the development and manufacturing of...

The release as fetched from its publisher. forgebiologics.com ↗